Suscribirse

Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure - 17/06/15

Doi : 10.1016/j.amjmed.2014.11.036 
Vikas Bhatia, MD a, b, , Navkaranbir S. Bajaj, MD a, b, Kumar Sanam, MD a, Taimoor Hashim, MD a, Charity J. Morgan, PhD a, Sumanth D. Prabhu, MD a, b, Gregg C. Fonarow, MD c, Prakash Deedwania, MD d, Javed Butler, MD, MPH e, Peter Carson, MD f, Thomas E. Love, PhD g, Raya Kheirbek, MD f, Wilbert S. Aronow, MD h, Stefan D. Anker, MD, PhD i, Finn Waagstein, MD, PhD j, Ross Fletcher, MD f, Richard M. Allman, MD k, Ali Ahmed, MD, MPH f
a University of Alabama at Birmingham, Birmingham, Ala 
b Veterans Affairs Medical Center, Birmingham, Ala 
c University of California, Los Angeles 
d University of California, San Francisco, Fresno 
e Stony Brook University, Stony Brook, NY 
f Veterans Affairs Medical Center, Washington, DC 
g Case Western Reserve University, Cleveland, Ohio 
h New York Medical College, Valhalla 
i Department of Innovative Clinical Trials, University Medical Centre Göttingen, Göttingen, Germany 
j University of Gothenburg, Gothenburg, Sweden 
k Department of Veterans Affairs, Geriatrics and Extended Care Services, Washington, DC 

Requests for reprints should be addressed to Vikas Bhatia, MD, University of Alabama at Birmingham, 1720 2nd Ave South, CH19-219, Birmingham AL 35294-2041.

Abstract

Background

Beta-blockers improve outcomes in patients with systolic heart failure. However, it is unknown whether their initial negative inotropic effect may increase 30-day all-cause readmission, a target outcome for Medicare cost reduction and financial penalty for hospitals under the Affordable Care Act.

Methods

Of the 3067 Medicare beneficiaries discharged alive from 106 Alabama hospitals (1998-2001) with a primary discharge diagnosis of heart failure and ejection fraction <45%, 2202 were not previously on beta-blocker therapy, of which 383 received new discharge prescriptions for beta-blockers. Propensity scores for beta-blocker use, estimated for each of the 2202 patients, were used to assemble a matched cohort of 380 pairs of patients receiving and not receiving beta-blockers who were balanced on 36 baseline characteristics (mean age 73 years, mean ejection fraction 27%, 45% women, 33% African American).

Results

Beta-blocker use was not associated with 30-day all-cause readmission (hazard ratio [HR] 0.87; 95% confidence interval [CI], 0.64-1.18) or heart failure readmission (HR 0.95; 95% CI, 0.57-1.58), but was significantly associated with lower 30-day all-cause mortality (HR 0.29; 95% CI, 0.12-0.73). During 4-year postdischarge, those in the beta-blocker group had lower mortality (HR 0.81; 95% CI, 0.67-0.98) and combined outcome of all-cause mortality or all-cause readmission (HR 0.87; 95% CI, 0.74-0.97), but not with all-cause readmission (HR 0.89; 95% CI, 0.76-1.04).

Conclusions

Among hospitalized older patients with systolic heart failure, discharge prescription of beta-blockers was associated with lower 30-day all-cause mortality and 4-year combined death or readmission outcomes without higher 30-day readmission.

El texto completo de este artículo está disponible en PDF.

Keywords : Beta-blockers, Hospitalization, Older adults, Readmission, Systolic heart failure


Esquema


 Funding: AA was in part supported by NIH grants (R01-HL085561 and R01-HL097047) from the NHLBI, Bethesda, Maryland and an intramural support from the UAB Comprehensive Cardiovascular Center.
 Conflicts of Interest: None.
 Authorship: All authors had access to the data and a role in writing the manuscript.


© 2015  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 128 - N° 7

P. 715-721 - juillet 2015 Regresar al número
Artículo precedente Artículo precedente
  • Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack
  • Virginia J. Howard, Rikki M. Tanner, Aaron Anderson, Marguerite R. Irvin, David A. Calhoun, Daniel T. Lackland, Suzanne Oparil, Paul Muntner
| Artículo siguiente Artículo siguiente
  • Peripherally Inserted Central Catheter-associated Deep Vein Thrombosis: A Narrative Review
  • Nabil Fallouh, Helen M. McGuirk, Scott A. Flanders, Vineet Chopra

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.